and difficulties in focusing CNV at the macular region and evaluating the localization of the foveola in relation to the neovascular tuft. Currently, there is no evidence from the randomized ...
Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback